Page 3 - Molecular Targeting Technologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Molecular targeting technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Molecular Targeting Technologies Today - Breaking & Trending Today

Lower dose, less toxic radiopharmaceutical produces better outcomes

E-Mail
Neuroendocrine tumours are cancers that begin in specialised cells called neuroendocrine cells. These cells have traits similar to those of nerve cells and hormone-producing cells. Neuroendocrine tumours, while rare, can occur anywhere in the body. Most affect the cardiothoracic region, eg lungs, appendix, small intestine, pancreas as well as the rectum. There are many types of neuroendocrine tumours: some grow slowly while others develop very rapidly.
Neuroendocrine tumors are characterised by abundant production of somatostatin receptor 2, a naturally circulating hormone that is an important target for scientists studying new treatment approaches.
Peptide Receptor Radionuclide Therapy (PRRT) is the most commonly used treatment for refractive neuroendocrine cancers, delivering cancer-killing radioactive substances directly to tumour sites. This treatment provides symptomatic relief, stopping or slowing tumour growth and improving overall survival for patients ....

Shawn Chen Xiaoyuan , Molecular Targeting Technologies Inc , Journal Of Nuclear Medicine , Chinese Academy Of Medical Science , National University Hospital , Yong Loo Lin School Of Medicine , Department Of Biomedical Engineering , Drug Administration , Union Medical College Hospital , National University Of Singapore , Department Of Diagnostic Radiology , Receptor Radionuclide Therapy , Peking Union Medical College Hospital , Chinese Academy , Medical Science , Professor Shawn Chen Xiaoyuan , Diagnostic Radiology , Yong Loo Lin School , National University , Prof Chen , Biomolecular Engineering , Biomedical Engineering , Nuclear Medicine , Professor Quek Swee Tian , Molecular Targeting Technologies , Investigational New Drug ,

FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc.

Press release content from Business Wire. The AP news staff was not involved in its creation.
FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc.
March 2, 2021 GMT
WEST CHESTER, Pa. (BUSINESS WIRE) Mar 2, 2021
Molecular Targeting Technologies, Inc. (MTTI), a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the approval of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). It enables a Phase I clinical study of the Safety and Dosimetry of its lead product, EBTATE ( 177 Lu-DOTA-EB-TATE), in patients with neuroendocrine tumors (NET). ....

United States , Chris Pak , Clinical Research Organization Newtown , Molecular Targeting Technologies Inc , National Institutes Of Health , Drug Administration , Targeting Technologies , Investigational New Drug , Precision Medicine , Targeted Radionuclide , National Institutes , Cell Thyroid , Clinical Research Organization , Molecular Targeting Technologies , Business Wire , Products And Services , Drug Approvals , Product Approvals , Product Testing , Diagnosis And Treatment , Health Care Industry , New Products And Services , Medical Biotechnology Industry , Clinical Trials , Medical Research , Drug Trials ,